Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.59 |
| ▸ | RELA | Q04206 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12897993 | 0.82 | HPGD (0.70) | HPGDRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL20221777 | 0.82 | HPGD (0.70) | HPGDRAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL29246728 | 0.82 | HPGD (0.69) | HPGDRAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL720937 | 0.81 | HPGD (0.68) | HPGDRAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL6263973 | 0.81 | HPGD (0.68) | HPGDRAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL8811234 | 0.81 | HPGD (0.68) | HPGDRAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL26051623 | 0.80 | HPGD (0.67) | HPGDRAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL12377802 | 0.80 | HPGD (0.67) | HPGDRAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL6245001 | 0.80 | HPGD (0.67) | HPGDRAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL8348993 | 0.79 | CYP1A2 (0.73) | HPGDRAB9ASMN1; SMN2NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116926578-A | Method for synthesizing heteroaryl thiophenol | 新疆大学 | 2023-10-24 | — | — | CN | disclosed |
| US-20200140425-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | MASSACHUSETTS GENERAL HOSPITAL | 2020-05-07 | — | — | US | disclosed |
| US-20200140425-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | MASSACHUSETTS GENERAL HOSPITAL | 2020-05-07 | — | — | US | disclosed |
| US-10301294-B2 | Compounds for the treatment of tuberculosis | The Broad Institute Inc. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301294-B2 | Compounds for the treatment of tuberculosis | The Broad Institute Inc. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | NIH - DEITR | 2016-02-04 | — | — | US | disclosed |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | NIH - DEITR | 2016-02-04 | — | — | US | disclosed |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | NIH - DEITR | 2016-02-04 | — | — | US | disclosed |
| WO-2014165090-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165090-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2005044008-A2 | 2 -AMINOTHIOPHENE COMPOUNDS AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| EP-0315997-B1 | Cephalosporin compounds and antibacterial agents | MEIJI SEIKA KAISHA (JP) | 1994-04-20 | — | — | EP | disclosed |
| EP-0209751-B1 | CEPHALOSPORIN DERIVATIVES AND BACTERICIDES CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 1992-09-16 | — | — | EP | disclosed |
| US-5028601-A | Substituted with an amino thiazole group and a dihydroxy-pyridone group | MEIJI SAIKA KAISHA, LTD. (JP) | 1991-07-02 | — | — | US | disclosed |
| US-4971961-A | ANTIBIOTICS AS BACTERICIDES AGAINST PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 1990-11-20 | — | — | US | disclosed |
| EP-0315997-A2 | Cephalosporin compounds and antibacterial agents | MEIJI SEIKA KAISHA LTD. (JP) | 1989-05-17 | — | — | EP | disclosed |
| EP-0289002-A2 | Novel cephalosporin compounds and antibacterial agents | MEIJI SEIKA KAISHA LTD. (JP) | 1988-11-02 | — | — | EP | disclosed |
| US-4758557-A | Cephalosporin derivatives and bactericides containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| EP-0209751-A2 | Cephalosporin derivatives and bactericides containing the same | MEIJI SEIKA KAISHA LTD. (JP) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301294-B2 | Compounds for the treatment of tuberculosis | GOT2, G6PD, FNTB | HPGD 382/4885RAB9A 3054/4885SMN1; SMN2 4593/4885 |
| US-20200140425-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GOT2, G6PD, FNTB | HPGD 382/4885RAB9A 3054/4885SMN1; SMN2 4593/4885 |
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | HPGD 1034/4885RAB9A 1525/4885SMN1; SMN2 2301/4885 |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GOT2, G6PD, FNTB | HPGD 382/4885RAB9A 3054/4885SMN1; SMN2 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.